It's an extremely positive note in regards to the group's view of the drug. In fact the comment that it's now just a dosing question (below) is very strong.
"While the announcement noted that the trial did not meet its primary endpoint at the 12 week mark, we understand this was SIMPLY THE RESULT OF UNDERDOSING (an insufficient amount of the drug entered the blood stream via the method of subcutaneous injection) and does not mean that the trial or the drug will be unsuccessful. "
As a very non technical shareholder in regards to Pharma all I have to go on is the announcements provided and from that info I couldn't make a call that it is clearly successful and just needs the dose sorted.
Does anyone have a feel for what basis Reitirewell may have to make such a strong statement? This is really at the core of whether this is going to $3 or $0.
And if this was the case it does place further questions over why they CBZ proposing such a big dilution, give the drug is an obvious success.
Add to My Watchlist
What is My Watchlist?